Fungating breast cancer occurs when a breast tumor grows through the skin’s surface, creating an open wound that can bleed, ooze, and produce a strong odor. Roughly 2% to 5% of locally advanced breast cancers reach this stage, in which malignant cells infiltrate the skin and cause breakdown, ulceration, and infection. The term “fungating” refers to the mushroom-like or cauliflower-like appearance the tumor can take as it erupts outward, though some wounds are flat, crater-shaped ulcerations instead. Despite how distressing these wounds are for patients and families, research on their management remains thin compared with other aspects of breast cancer care.
How a Breast Tumor Breaks Through the Skin
A fungating wound forms when a growing mass of cancer cells pushes outward from deeper tissue, infiltrating the dermis and epidermis until the skin can no longer contain it. Blood supply to the overlying skin gets disrupted along the way, causing tissue to die and break down. The result is an open wound that sits on top of an active tumor, which means the wound cannot heal through the normal repair process. New cancer cells keep arriving faster than the body can close the defect, and the fragile, abnormal blood vessels within the tumor bleed easily with minimal contact.
Once the surface is breached, the wound becomes colonized by bacteria, particularly anaerobic species that thrive in the oxygen-poor, necrotic tissue of the tumor bed. It is these bacteria that drive many of the wound’s most troubling symptoms, especially malodor and heavy discharge. The wound may grow slowly over weeks or expand rapidly, depending on the aggressiveness of the underlying cancer and whether systemic treatment is keeping the disease in check.
Why These Wounds Often Appear Late
Fungating breast wounds almost always represent advanced disease, but the delay between first noticing a lump and presenting with a skin-breaking tumor is often longer than clinicians expect. In a study at a tertiary care hospital in Pakistan, the most common reasons patients gave for delay included poverty, reliance on traditional faith healers, cultural myths about treatment, fear of surgery, and resistance from family members. Nearly 20% of patients in that study held specific misconceptions, such as the belief that biopsy needles or surgery would worsen the cancer.
Research from a U.S. surgical series echoed a similar pattern in a different cultural context: embarrassment about the wound’s appearance and fear of treatment were among the reasons patients cited for putting off medical care. The psychological barrier is self-reinforcing. As the wound grows and begins to smell, patients withdraw socially, which makes them even less likely to seek help. By the time they do present, many already have lymph node involvement or distant metastases. In one series from a low- and middle-income country, 87% of patients with fungating breast cancer had axillary lymph node involvement and 42% had distant metastases at diagnosis, with a mean tumor size of about 8 cm.
The Problem of Wound Odor
For many patients, the smell is the single most distressing symptom. It can be strong enough to fill a room, and patients frequently describe it as the reason they stop leaving their homes or allowing visitors. The odor comes from volatile organic compounds produced by anaerobic bacteria living in the necrotic tissue. Microbiome profiling of these wounds has identified specific anaerobic genera, including Bacteroides, Prevotella, Peptostreptococcus, and Fusobacterium, as the principal producers of the chemicals responsible for the smell. The presence of even one strain of obligate anaerobic bacteria has been linked to severe odor and heavy discharge.
The frontline treatment for wound odor is topical metronidazole, an antibiotic that targets anaerobic bacteria. In a multicenter phase III trial of metronidazole 0.75% gel, the clinical success rate for odor control reached about 95% after two weeks of use, and anaerobic bacteria detected at baseline were absent at the follow-up assessment. Roughly 70% of patients rated their satisfaction as markedly or moderately improved. When the gel formulation is unavailable or too expensive, clinicians sometimes crush oral metronidazole tablets and sprinkle them directly onto the wound. A case report described this approach in a patient with triple-negative breast cancer who had multiple fungating tumors on her chest wall and arm. Crushed 500 mg tablets applied twice daily produced an immediate reduction in odor and reduced wound discharge within days.
Other topical approaches have been explored. A Cochrane systematic review comparing manuka honey-coated dressings with nanocrystalline silver-coated dressings found no statistically significant difference in their effect on exudate, odor, or wound pain. The evidence base for most alternative wound products remains small, and metronidazole continues to be the most widely used and best-studied agent for this specific problem.
Bleeding and How It Is Controlled
Tumor blood vessels are structurally abnormal. They lack the smooth muscle that helps normal vessels constrict when damaged, so even light friction from clothing or a dressing change can trigger bleeding that is hard to stop. For most day-to-day bleeding, absorbent wound dressings are the first line of defense. Calcium alginate dressings, which form a gel on contact with blood and promote clotting, are commonly used, and at least one randomized trial has been designed to compare them head-to-head with regenerated oxidized cellulose dressings for bleeding control in malignant breast wounds.
When bleeding is more severe or recurrent, topical hemostatic agents can help. A case report described successful hemostasis using a gelatin-thrombin matrix (Floseal) combined with local dressing in a patient whose fungating breast cancer wound bled uncontrollably with standard measures. For the rare but life-threatening hemorrhage that cannot be managed at the wound surface, interventional radiologists can perform transcatheter arterial embolization, threading a catheter into the blood vessel feeding the tumor and blocking it with particles or coils. Multiple case reports have documented this approach as a way to stop massive bleeding when surgery is not feasible due to tumor size or the patient’s overall condition.
Palliative Radiation for Symptom Relief
Radiation therapy is not always about trying to cure the cancer. In fungating breast wounds, palliative radiation can shrink the tumor enough to reduce bleeding, discharge, pain, and odor, sometimes dramatically. In a study of patients who received fractionated palliative radiation for symptomatic advanced breast cancer, 91% reported that bleeding stopped, 78% had decreased wound discharge, 72% experienced less pain and reduced need for narcotic medication, and 75% noticed a decrease in odor. Even a single radiation treatment can work: in the same study’s single-fraction group, 80% of patients had no recurrent bleeding and 75% reported less pain.
A case report described an elderly patient with a fungating breast cancer wound whose bleeding was controlled with a single 8 Gy dose of radiation, with hemostasis lasting longer than anticipated. The authors suggested that single-fraction radiation can be especially valuable for older or frailer patients who cannot tolerate a longer course of treatment, offering meaningful symptom relief with just one hospital visit.
Pain at the Wound Edge
Pain from fungating wounds is complex. It can be a constant background ache from the tumor pressing on surrounding tissue, or it can be sharp and procedural, triggered by dressing changes. Interestingly, research on topical lidocaine for cancer wound pain found that the pain is not uniform across the wound surface. It tends to be most intense at the border between the ulcerated area and the surrounding normal skin, likely because nerve endings at that transition zone are being actively stimulated and sensitized. This finding has practical implications: applying topical anesthetic specifically to the wound margins before a dressing change, rather than evenly across the whole wound, may give better pain relief.
For background pain, systemic analgesics following standard cancer pain guidelines remain the backbone of treatment. But the wound-specific pain, especially during care procedures, often needs a layered approach combining topical anesthetics, gentle non-adherent dressings that can be removed without tearing new tissue, and careful timing of oral pain medication before scheduled dressing changes.
Surgery When the Goal Is Comfort
When people hear “surgery for cancer,” they usually picture an operation intended to remove the disease. In fungating breast cancer, surgery often serves a different purpose: removing enough of the ulcerated, infected, bleeding tissue to relieve symptoms and improve quality of life, even when cure is not possible. This is called a “toilet mastectomy,” a term that comes from the French word “toilette” meaning cleansing or tidying, not from the English bathroom fixture.
A series from Nepal found that the most common reasons for performing palliative mastectomy were fungation, bleeding, ulceration, and infected, foul-smelling discharge. A comparative study at a tertiary hospital found that toilet mastectomy produced a lower rate of wound infection (about 15%) compared with simple mastectomy (about 41%) in patients with fungating tumors, though the difference did not reach statistical significance in that small sample. The goal of these operations is not to achieve tumor-free margins but to debulk enough diseased tissue that the remaining wound can be managed and the patient can function more comfortably.
Electrochemotherapy for Skin-Level Disease
Electrochemotherapy is a technique that combines a chemotherapy drug, usually bleomycin, with brief electrical pulses delivered through electrodes placed on or around the tumor. The electrical pulses temporarily open tiny pores in the cancer cell membranes, allowing much higher concentrations of the drug to enter the cells than intravenous chemotherapy alone could achieve. This makes it possible to treat visible skin-level disease directly, even when the tumor has stopped responding to standard systemic treatment.
Early clinical experience with electrochemotherapy in breast cancer reported objective response rates up to 90%, with roughly 59% of patients achieving complete local remission. More recent data following standardized European protocols have confirmed sustained complete response rates in the range of 26% to 58%, with durable local control. In a prospective cohort study, about 74% of patients showed a good or excellent response based on clinical photographs. One case report described a patient with a large fungating chest wall lesion that was unresponsive to systemic chemotherapy. After three rounds of electrochemotherapy with intravenous bleomycin, she achieved a complete response with extensive re-epithelialization of the wound and no obvious local disease 18 months later.
Electrochemotherapy is not widely available everywhere, and it works best on disease that is confined to the skin and superficial tissue rather than deep invasion. But for patients whose fungating wounds are resistant to other treatments, it represents a genuinely effective option that can restore skin integrity in ways that seem improbable given the severity of these wounds.
Systemic Treatment and Tumor Subtype
The choice and effectiveness of systemic therapy for fungating breast cancer depends heavily on the tumor’s biological subtype. A systematic review found that treatment intensity scaled with subtype complexity: luminal-B cancers averaged about two treatment modalities, HER2-positive cases averaged three, and over half of HER2-positive patients achieved a complete response. Triple-negative breast cancers, the subtype with the fewest targeted therapy options, also averaged two modalities, but only about half showed even a partial response.
Newer approaches are being investigated. A phase Ib trial tested intratumoral injection of talimogene laherparepvec (T-VEC), an oncolytic virus therapy, combined with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. Of the 18 patients whose injection sites were clinically evaluated, about 44% had a partial local response and another 39% had stable disease locally. Patients with higher pre-treatment levels of tumor-infiltrating immune cells were more likely to respond, suggesting that the treatment works partly by awakening the local immune response against the tumor. While these are early-stage results, they point toward a future in which injectable therapies could be delivered directly into fungating wounds to control local disease without requiring surgery or radiation.
The Emotional Weight on Patients and Caregivers
Fungating breast wounds impose a psychological burden that goes well beyond what the physical symptoms alone would suggest. The wound is visible. It smells. It leaks through clothing. For many patients, it becomes a constant, undeniable reminder that their cancer is advancing, and they cannot hide it from the people around them. Research on body image in advanced breast cancer has found that body image disturbances contribute to emotional distress, reduced intimacy, and social isolation, with greater body dissatisfaction linked to measurably lower quality of life.
A qualitative study described patients with malignant fungating wounds as living in an “unbounded body,” struggling with the erosion of their physical boundaries. Most patients and their informal caregivers reported being largely on their own, lacking information and advice about how to manage the wound, and feeling constrained by copious discharge, odor, and bleeding. The wound gradually became the center of both the patient’s and the caregiver’s daily life, with enormous amounts of time spent trying to keep symptoms under control.
Caregivers face their own form of suffering. Research on informal carers of people with malignant fungating wounds found that the visibility of the cancer was one of the most shocking aspects to deal with. The wound’s presence and the advanced stage of disease it represents fundamentally changed the relationship between patient and carer. Despite problems with odor and uncontrollable discharge, caregivers did their best to help, but all of them managed the wound without professional guidance, all of them found it a major burden, and all reported feeling isolated. These findings suggest that healthcare systems routinely fail to support the people providing daily wound care at home, even when the demands of that care are extreme.
Prognosis and Survival
Fungating breast cancer carries a wide range of outcomes, depending on the stage at diagnosis, tumor biology, and access to treatment. A study from a low- and middle-income country reported a median survival of 36 months and a five-year overall survival rate of 40%. That cohort had a high proportion of stage III and IV disease, with 58% at stage III and 42% at stage IV. A separate surgical series that included wound closure procedures reported a mortality rate of about 32% during follow-up and an estimated mean overall survival of roughly 56 months, though with a wide confidence interval.
These numbers are difficult to generalize because the populations studied vary enormously in disease stage, treatment access, and tumor subtype. What the data make clear is that fungating breast cancer is not automatically a terminal diagnosis in the short term. Many patients live for years, which makes symptom management and quality of life all the more important. Treating a fungating wound as “just palliative” and neglecting active symptom control means condemning someone to potentially years of avoidable suffering.
Ethical Complexities in Real-World Care
Textbook descriptions of treatment assume a patient who can understand their options, consent to care, attend appointments, and manage a wound care routine at home. In practice, fungating breast cancer often presents in people whose circumstances make standard care pathways impossible. A case presented at a palliative care conference described a 52-year-old woman with untreated schizophrenia and metastatic fungating breast cancer whose psychiatric condition prevented her from safely managing outpatient chemotherapy, and whose lack of psychosocial support meant she could not be discharged to live alone. Her cancer progressed despite inpatient treatment attempts, and she was ultimately enrolled in hospice by her family.
Cases like these expose tensions that clinicians face regularly but that rarely appear in clinical trial data: how to deliver wound care to someone experiencing psychosis, how to manage a tumor that requires daily dressing changes when the patient is homeless, how to respect a patient’s refusal of treatment when that refusal stems from delusional thinking rather than informed choice. These patients are not outliers. Fungating wounds disproportionately affect people who delay care, and the reasons for delay, including poverty, lack of access, mental illness, and cultural barriers, tend to cluster in the same individuals. The wound itself then becomes another barrier, as the stigma of its appearance and smell makes it even harder to engage with the healthcare system.
Arterial Embolization for Emergency Bleeding
While most bleeding from fungating breast wounds is manageable with topical measures, a small number of patients experience sudden, severe hemorrhage that can be life-threatening. In these emergencies, when surgery is not feasible and dressings cannot control the blood loss, interventional radiology offers a minimally invasive alternative. Transcatheter arterial embolization involves guiding a catheter through the arterial system to the vessel supplying the bleeding tumor and blocking it with embolic material.
Multiple case reports have documented this technique as an effective way to achieve rapid hemostasis. One report described a patient with recurrent locally advanced breast cancer who presented with sudden severe bleeding that was stopped entirely by embolization. Another documented successful particle embolization in a patient with life-threatening hemorrhage from a fungating carcinoma, concluding that embolization alone can definitively manage the bleeding and allow the patient to avoid emergency surgery. A broader case series noted that embolization offers a particularly valuable option when the tumor’s size or the patient’s medical condition makes an operation too risky. Although the evidence consists entirely of case reports and small series rather than randomized trials, the consistent success described across multiple centers makes embolization a recognized tool in the management of catastrophic tumor bleeding.